NLRP3 and Parkinson disease: P38 inhibitors could increase the translocation of TFEB from the cytoplasm to the nucleus, and ultimately facilitates NLRP3 degradation via the lysosomal pathway, reducing α‐synuclein levels in PD mice and attenuating neuroinflammation caused by abnormal protein accumulation.79